Company Overview and News

NBN discounts criticised for ‘pricing out’ small telcos

Smaller providers have slammed the National Broadband Network's pricing discounts as giving the big four an unfair advantage.

NBN discounts criticised for ‘pricing out’ small telcos

Smaller providers have slammed the National Broadband Network's pricing discounts as giving the big four an unfair advantage.

Inabox Group in a cloud conundrum as Hostworks dampens financials

Inabox Group Ltd (ASX:IAB) shares have plunged 36% to $0.64 in the first 15 minutes of trade, following the company being re-instated after a trading halt.

Inabox Group calls for halt concerning cloud business

Inabox Group Ltd (ASX:IAB) has been granted a trading halt by the ASX this morning, pending developments concerning its Hostworks business.

Inabox Group continues to gain strong sales momentum

Inabox Group (ASX:IAB) finished FY17 with strong momentum in all areas of its business, with unaudited full year revenue expected to be $90 million and underlying EBITDA of $6 million.

Inabox grows WA presence with Logic buy

Listed communications and ICT services provider Inabox Group has grown its local presence with the acquisition of Perth-based Logic Communications for $1.5 million in cash.

Inabox Group to reveal transaction

Inabox Group (ASX:IAB) has been granted a trading halt by the ASX, pending details of a pending financing transaction.

Business thinking inside the box

SYDNEY IT provider Inabox Group has acquired Adelaide cloud and hosting services business Hostworks in a deal worth $7 million.

Investor Presentation



Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...